Systemic sclerosis

被引:229
作者
Volkmann, Elizabeth R. [1 ,2 ,7 ]
Andreasson, Kristofer [3 ]
Smith, Vanessa [4 ,5 ,6 ]
机构
[1] Univ Calif Los Angeles, Dept Med, Div Rheumatol, Los Angeles, CA 90095 USA
[2] David Geffen Sch Med, Los Angeles, CA USA
[3] Lund Univ, Dept Rheumatol, Lund, Sweden
[4] Ghent Univ Hosp, Dept Internal Med, Ghent, Belgium
[5] Ghent Univ Hosp, Dept Rheumatol, Ghent, Belgium
[6] VIB Inflammat Res Ctr, Unit Mol Immunol & Inflammat, Ghent, Belgium
[7] Univ Calif Los Angeles, Dept Med, Div Rheumatol, Los Angeles, CA 90095 USA
关键词
PULMONARY-ARTERIAL-HYPERTENSION; INTERSTITIAL LUNG-DISEASE; STEM-CELL TRANSPLANTATION; CONTINUOUS INTRAVENOUS EPOPROSTENOL; SCLERODERMA RENAL CRISIS; DOUBLE-BLIND; CONNECTIVE-TISSUE; MYCOPHENOLATE-MOFETIL; PROSTACYCLIN ANALOG; SKIN THICKNESS;
D O I
10.1016/S0140-6736(22)01692-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Systemic sclerosis, also known as scleroderma, is a rare and complex autoimmune connective-tissue disease. Once considered an untreatable and unpredictable condition, research advancements have improved our understanding of its disease pathogenesis and clinical phenotypes and expanded our treatment armamentarium. Early and accurate diagnosis is essential, while ongoing efforts to risk stratify patients have a central role in predicting both organ involvement and disease progression. A holistic approach is required when choosing the optimal therapeutic strategy, balancing the side-effect profile with efficacy and tailoring the treatment according to the goals of care of the patient. This Seminar reviews the multiple clinical dimensions of systemic sclerosis, beginning at a precursor very early stage of disease, with a focus on timely early detection of organ involvement. This Seminar also summarises management considerations according to the pathological hallmarks of systemic sclerosis (eg, inflammation, fibrosis, and vasculopathy) and highlights unmet needs and opportunities for future research and discovery.
引用
收藏
页码:304 / 318
页数:15
相关论文
共 176 条
  • [1] The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy
    Ahlmann, Martina
    Hempel, Georg
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (04) : 661 - 671
  • [2] Mycophenolate mofetil and its mechanisms of action
    Allison, AC
    Eugui, EM
    [J]. IMMUNOPHARMACOLOGY, 2000, 47 (2-3): : 85 - 118
  • [3] Therapeutic Approaches for Treating Pulmonary Arterial Hypertension by Correcting Imbalanced TGF-β Superfamily Signaling
    Andre, Patrick
    Joshi, Sachindra R.
    Briscoe, Steven D.
    Alexander, Mark J.
    Li, Gang
    Kumar, Ravindra
    [J]. FRONTIERS IN MEDICINE, 2022, 8
  • [4] COVID-19 vaccination and antirheumatic therapy
    Arnold, Jack
    Winthrop, Kevin
    Emery, Paul
    [J]. RHEUMATOLOGY, 2021, 60 (08) : 3496 - 3502
  • [5] Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung disease
    Assassi, Shervin
    Volkmann, Elizabeth R.
    Zheng, W. Jim
    Wang, Xuan
    Wilhalme, Holly
    Lyons, Marka A.
    Roth, Michael D.
    Tashkin, Donald P.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (06) : 854 - 860
  • [6] Predictors of Fatigue Severity in Early Systemic Sclerosis: A Prospective Longitudinal Study of the GENISOS Cohort
    Assassi, Shervin
    Leyva, Astrud L.
    Mayes, Maureen D.
    Sharif, Roozbeh
    Nair, Deepthi K.
    Fischbach, Michael
    Ngan Nguyen
    Reveille, John D.
    Gonzalez, Emilio B.
    McNearney, Terry A.
    [J]. PLOS ONE, 2011, 6 (10):
  • [7] Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group
    Avouac, J.
    Fransen, J.
    Walker, U. A.
    Riccieri, V.
    Smith, V.
    Muller, C.
    Miniati, I.
    Tarner, I. H.
    Bellando Randone, S.
    Cutolo, M.
    Allanore, Y.
    Distler, O.
    Valentini, G.
    Czirjak, L.
    Mueller-Ladner, U.
    Furst, D. E.
    Tyndall, A.
    Matucci-Cerinic, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (03) : 476 - 481
  • [8] Transforming growth factor-beta signaling in systemic sclerosis
    Ayers, Nolan B.
    Sun, Chenming
    Chen, Shi-You
    [J]. JOURNAL OF BIOMEDICAL RESEARCH, 2018, 32 (01): : 3 - 12
  • [9] Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease -: A randomized, controlled trial
    Badesch, DB
    Tapson, VF
    McGoon, MD
    Brundage, BH
    Rubin, LJ
    Wigley, FM
    Rich, S
    Barst, RJ
    Barrett, PS
    Kral, KM
    Jöbsis, MM
    Loyd, JE
    Murali, S
    Frost, A
    Girgis, R
    Bourge, RC
    Ralph, DD
    Elliott, CG
    Hill, NS
    Langleben, D
    Schilz, RJ
    McLaughlin, VV
    Robbins, IM
    Groves, BM
    Shapiro, S
    Medsger, TA
    Gaine, SP
    Horn, E
    Decker, JC
    Knobil, K
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 132 (06) : 425 - +
  • [10] Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling
    Barbacki, Ariane
    Baron, Murray
    Wang, Mianbo
    Zhang, Yuqing
    Stevens, Wendy
    Sahhar, Joanne
    Proudman, Susanna
    Nikpour, Mandana
    Man, Ada
    [J]. ARTHRITIS CARE & RESEARCH, 2023, 75 (03) : 640 - 647